

Seeking Preclinical Pancreatic Cancer Models for Drug Distribution Studies

Daiichi Sankyo, a global pharmaceutical company, is seeking advanced **preclinical models of pancreatic cancer** that more closely **replicate the clinical tumor microenvironment** than conventional models. Models that support **drug distribution and pharmacokinetic studies** are also welcome.



Approaches of Interest:

- **Advanced *in vivo* models**, such as genetically engineered mouse models, patient-derived xenografts, syngeneic models, or humanized models, that reproduce the tumor microenvironment of clinical pancreatic cancer such as tumor-stroma ratio, stromal composition, and vascular architecture of pancreatic cancer
- **Advanced *ex vivo* systems**, such as pancreatic cancer slice cultures, fresh patient tumor explants and perfused tissue systems, that support high-throughput assessment of distribution and tissue penetration of drugs
- **Models paired with quantitative evaluation methods**, including three-dimensional assessment of intratumoral drug distribution and tumor cell drug exposure following administration, as well as relevant imaging and analysis approaches
- **Pancreatic ductal adenocarcinoma models** will be prioritized and **both primary and metastatic disease models** will be considered

Out of Scope:

- Models based solely on orthotopic transplantation of cancer cell lines into the pancreas
- *In vitro* models, including organoids
- Proposals describing an evaluation or imaging system alone, without an accompanying model
- Well-established models and culture systems that do not incorporate novel technology

Developmental Stages of Interest:

- Opportunities from basic research through late preclinical development are within scope
- Models providing *ex vivo* evidence that can be correlated with clinical outcomes are of particular interest

Submission Information

Daiichi Sankyo invites applications from both academic institutions and industry organizations. Submission of one-page, **200–300-word briefs** are highly encouraged, along with **supplementary information e.g. slide decks and relevant publications**. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Opportunities sought

-  Company profiles
-  Research projects
-  Centres of excellence
-  Technologies

Submissions

Please submit relevant, non-confidential opportunities online [here](#)

Deadline: **2nd November 2026 - 11:59 pm GMT**

Have any questions?

Contact our team at campaigns@inpart.io

